Clinical Research in ALS & Related Disorders for Therapeutic Development (CReATe) - Administrative Core
ALS 临床研究
基本信息
- 批准号:10020811
- 负责人:
- 金额:$ 31.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-30 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AdvocacyAmyotrophic Lateral SclerosisAustraliaBiologicalBiological MarkersBiometryCaregiversCaringCertificationClinicClinical ResearchCognitiveCollectionCommunicationCommunitiesDataDiseaseElectronic Health RecordEnrollmentEnsureEnvironmental ExposureEpidemiologistEuropeEvolutionFamily CaregiverFamily memberFosteringFoundationsFrontotemporal DementiaFundingGeneticGenomicsGenotypeGoalsHealth care facilityHereditary Spastic ParaplegiaInstitutionMissionMotorMuscular DystrophiesNeurodegenerative DisordersOutcomePatientsPhenotypePilot ProjectsPopulation StudyPrimary Lateral SclerosisProcessProductivityProgressive Muscular AtrophyProtocols documentationRare DiseasesRegistriesResearchResearch ActivityResourcesSaint Jude Children&aposs Research HospitalSamplingScienceSouth AfricaSpastic ParaplegiaStandardizationSteelStructureSystemTrainingUniversitiesbiobankclinical phenotypeclinical research sitedata managementdata warehousefrontotemporal degenerationgenomic dataimprovedmembermultidisciplinaryoutreachpatient advocacy grouppatient populationphenotypic dataprotocol developmentsynergismtherapeutic developmentwhole genome
项目摘要
Project Summary / Abstract
The Administrative Core of the CReATe Consortium is responsible for coordinating and supporting all activities
of the CReATe Consortium, to enable this Rare Diseases Clinical Research Consortium (RDCRC) to achieve
its scientific, educational and stakeholder engagement goals, and to function effectively as part of the Rare
Diseases Clinical Research Network (RDCRN). The Administrative Core is responsible for providing project
management as well as data management & biostatistical support, oversight of the CReATe biorepository and
genomic activity, and outreach & liaison activities. As such, the Administrative Core serves as a hub for the
Consortium, with the principal goals of enabling efficient protocol development and execution; facilitating
communication both within the Consortium and with patient advocacy groups and other key stakeholders; and
partnering with the RDCRN Data Management and Coordinating Center (DMCC) to specifically foster Network
activities and to promote rare disease research more generally. The specific aims for the Administrative Core,
as part of this renewal application, are to: (1) implement efficient and effective processes that support the
scientific rigor and productivity of the CReATe Consortium’s research activities; (2) promote collaborative
partnership with patient advocacy groups and other strategic partners, including patients, family members and
caregivers; and (3) develop and disseminate resources that are valuable to the broader scientific community
engaged in ALS and related disorders research. These include the CReATe Data Repository, the CReATe
Biorepository, CReATe genomic data (available through the St. Jude Cloud) and the ALS Toolkit, a module
developed within the Epic electronic health record, that facilitates the systematic collection of structured
clinical/phenotypic data from patients receiving care in a multi-disciplinary ALS clinic.
项目摘要/摘要
CREATE联盟的行政核心负责协调和支持所有活动
CREATE联盟,使这个罕见疾病临床研究联盟(RDCRC)能够实现
其科学、教育和利益攸关方的参与目标,并作为罕见的
疾病临床研究网络(RDCRN)。行政核心负责提供项目
管理以及数据管理和生物统计支持,监督CREATE生物库和
基因组活动,以及外展和联络活动。因此,管理核心充当
联合体,其主要目标是促进有效的议定书制定和执行;促进
在联盟内部以及与患者权益倡导团体和其他关键利益攸关方进行沟通;以及
与RDCRN数据管理和协调中心(DMCC)合作,专门促进网络
活动,并更广泛地促进罕见病研究。行政核心的具体目标,
作为续签申请的一部分,将:(1)实施高效和有效的流程,以支持
CREATE联盟研究活动的科学严谨性和生产力;(2)促进合作
与患者倡导团体和其他战略合作伙伴建立伙伴关系,包括患者、家属和
护理人员;以及(3)开发和传播对更广泛的科学界有价值的资源
从事肌萎缩侧索硬化症及相关疾病研究。其中包括创建数据存储库、创建
创建基因组数据(可通过圣裘德云获得)和肌萎缩侧索硬化工具包,这是一个模块
在Epic电子健康记录内开发,便于系统地收集结构化的
在多学科ALS诊所接受治疗的患者的临床/表型数据。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael Benatar其他文献
Michael Benatar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael Benatar', 18)}}的其他基金
Multi-Center ALS Biomarker Validation Study (CReATe Biomarkers)
多中心 ALS 生物标志物验证研究 (CReATe Biomarkers)
- 批准号:
10410344 - 财政年份:2018
- 资助金额:
$ 31.45万 - 项目类别:
University of Miami NeuroNEXT Trial Site
迈阿密大学 NeuroNEXT 试验网站
- 批准号:
10201771 - 财政年份:2018
- 资助金额:
$ 31.45万 - 项目类别:
Multi-Center ALS Biomarker Validation Study (CReATe Biomarkers)
多中心 ALS 生物标志物验证研究 (CReATe Biomarkers)
- 批准号:
10612967 - 财政年份:2018
- 资助金额:
$ 31.45万 - 项目类别:
University of Miami NeuroNEXT Trial Site
迈阿密大学 NeuroNEXT 试验网站
- 批准号:
10593638 - 财政年份:2018
- 资助金额:
$ 31.45万 - 项目类别:
University of Miami NeuroNEXT Trial Site
迈阿密大学 NeuroNEXT 试验网站
- 批准号:
9980517 - 财政年份:2018
- 资助金额:
$ 31.45万 - 项目类别:
Clinical Centers for the NINDS NeuroNEXT(Network of Excellence in Neuroscience Clinical Trials) Consortium
NINDS NeuroNEXT(神经科学临床试验卓越网络)联盟的临床中心
- 批准号:
10744345 - 财政年份:2018
- 资助金额:
$ 31.45万 - 项目类别:
Pre-Symptomatic Familial ALS (Pre-fALS) Study - Prelude to a Treatment Trial
症状前家族性 ALS (Pre-fALS) 研究 - 治疗试验的前奏
- 批准号:
10237152 - 财政年份:2018
- 资助金额:
$ 31.45万 - 项目类别:
Pre-Symptomatic Familial ALS (Pre-fALS) Study - Prelude to a Treatment Trial
症状前家族性 ALS (Pre-fALS) 研究 - 治疗试验的前奏
- 批准号:
10469619 - 财政年份:2018
- 资助金额:
$ 31.45万 - 项目类别:
Pre-Symptomatic Familial ALS (Pre-fALS) Study - Prelude to a Treatment Trial
症状前家族性 ALS (Pre-fALS) 研究 - 治疗试验的前奏
- 批准号:
10001608 - 财政年份:2018
- 资助金额:
$ 31.45万 - 项目类别:
Multi-Center ALS Biomarker Validation Study (CReATe Biomarkers)
多中心 ALS 生物标志物验证研究 (CReATe Biomarkers)
- 批准号:
9923007 - 财政年份:2018
- 资助金额:
$ 31.45万 - 项目类别:
相似海外基金
Amyotrophic Lateral Sclerosis: treating the circuit behind the disease
肌萎缩侧索硬化症:治疗疾病背后的回路
- 批准号:
MR/Y014901/1 - 财政年份:2024
- 资助金额:
$ 31.45万 - 项目类别:
Research Grant
Dysregulation of RNA processing as a driver of motor neuron dysfunction in Amyotrophic Lateral Sclerosis
RNA 加工失调是肌萎缩侧索硬化症运动神经元功能障碍的驱动因素
- 批准号:
MR/Y014286/1 - 财政年份:2024
- 资助金额:
$ 31.45万 - 项目类别:
Research Grant
Fasciculation IN Amyotrophic Lateral Sclerosis Using MUMRI (FINALSUM)
使用 MUMRI 治疗肌萎缩侧索硬化症的肌束颤动 (FINALSUM)
- 批准号:
MR/Y503502/1 - 财政年份:2024
- 资助金额:
$ 31.45万 - 项目类别:
Research Grant
I-Corps: Developing A Blood-Based Biomarker for the Detection and Monitoring of Amyotrophic Lateral Sclerosis
I-Corps:开发一种基于血液的生物标志物,用于检测和监测肌萎缩侧索硬化症
- 批准号:
2317745 - 财政年份:2023
- 资助金额:
$ 31.45万 - 项目类别:
Standard Grant
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)
开发 CM-CS1 CAR Treg 治疗肌萎缩侧索硬化症 (ALS)
- 批准号:
10696512 - 财政年份:2023
- 资助金额:
$ 31.45万 - 项目类别:
Targeted immunotherapy for amyotrophic lateral sclerosis and frontotemporal dementia
肌萎缩侧索硬化症和额颞叶痴呆的靶向免疫治疗
- 批准号:
10759808 - 财政年份:2023
- 资助金额:
$ 31.45万 - 项目类别:
Metrics for Brain Controlled Communication: A comprehensive review of clinical outcome assessments for communication brain computer interfaces in amyotrophic lateral sclerosis
脑控制通信指标:肌萎缩侧索硬化症通信脑机接口临床结果评估的全面综述
- 批准号:
10848139 - 财政年份:2023
- 资助金额:
$ 31.45万 - 项目类别:
Resolving the Role of Neuronal STING in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
解决神经元 STING 在肌萎缩侧索硬化症和额颞叶痴呆中的作用
- 批准号:
10606865 - 财政年份:2023
- 资助金额:
$ 31.45万 - 项目类别:
The Gut Microbiota as a Contributor to Sexual Dimorphism in Amyotrophic Lateral Sclerosis
肠道微生物群是肌萎缩侧索硬化症性别二态性的一个促成因素
- 批准号:
488892 - 财政年份:2023
- 资助金额:
$ 31.45万 - 项目类别:
Operating Grants
The biochemical stratification of amyotrophic lateral sclerosis
肌萎缩侧索硬化症的生化分层
- 批准号:
MR/Y001095/1 - 财政年份:2023
- 资助金额:
$ 31.45万 - 项目类别:
Fellowship